Predictive Biosciences is focused on developing urine and tissue-based tests for bladder and prostate cancer. Our CertNDx tests are commercially available for use in hematuria assessment, recurrence monitoring and molecular grading. We continue to add additional biomarkers to our portfolio to increase the clinical performance of existing assays and expand our pipeline of molecular tests across different urological cancers.
*These products are laboratory-developed tests (LDT) provided as a service to physicians. These products are not in-vitro diagnostic (IV) kits and are not sold directly to patients or to other laboratories.